







































Pain in the neurodegenerating brain: insights into
pharmacotherapy for Alzheimer disease and
Parkinson disease
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1. Introduction
The effects of neurodegeneration on the experience of pain remain
poorly understood, despite the risk of suffering from both pain and
neurodegenerative diseases rising concurrently with age.63,75 Given
the anticipated increase in magnitude and median age of the global
population,76,152 the interaction of these 2 clinically unmet needs will
become an increasingly pressing challenge. In particular, a
significant proportion of patients with Alzheimer disease (AD) and
Parkinson disease (PD), the 2 most prevalent neurodegenerative
diseases, suffer chronic pain of variable origin (Box 1). As such, they
have been the most extensively studied and, for brevity, will be the
focus of this review. Persistent pain in AD and PD is partially
attributable to various concomitant disease manifestations and
comorbidities (Fig. 1).43,117 In addition, disease-specific neurode-
generative changes may affect a multitude of regions implicated in
the perceptual and cognitive processes underlying pain. Despite
this, the precise perceptual sequelae of neurodegenerative patho-
physiology in these 2 diseases remain equivocal, and whether this
may result in differential responses to analgesic treatment remains
largely unexplored.
Three key principles lay conceptual foundations for the
investigation of the effects of neurodegenerative pathophysiology
on treatment mechanisms: (1) a given intensity of stimulus
produces heterogeneous levels of reported pain and unpleas-
antness,30,60,110,109,111,154 (2) genetic and environmental factors
predispose some to chronic pain,1,47,48,87 and (3) diversity of pain
physiology and pathophysiology results in heterogeneous re-
sponses to pharmacotherapy46,100,134,153. Collectively, these
support the notion that heterogeneous physiology and patho-
physiology can give rise to divergent treatment responses. Within
this framework, neurodegeneration and its effects on the central
nervous system can be considered as one such external factor
contributing to heterogeneity, resulting in putative perturbation of
pain processing (1 and 2) and responses to analgesic treatments
(3) (Fig. 1).
Chronic pain in AD and PD not only impacts patients’ quality of
life but also presents a formidable healthcare and socioeconomic
challenge. Drugs available for treatment of chronic pain are
associated with high numbers needed to treat and may have
serious side effects.145 Moreover, poorly managed pain is
associated with depression,33 anxiety,139 and functional loss.38
Given the high prevalence of pain and frailty in these patient
groups, clear scientific rationale is imperative to ensure safe and
effective clinical management (Fig. 2). In this article, we discuss
pain processing and perception in AD and PD as well as its
emerging relevance to pharmacological treatment.
2. Alzheimer disease
Alzheimer disease is the most common form of dementia
affecting more than 45 million people worldwide119 and is
clinically characterised by progressive cognitive deteriora-
tion.25,43,77 The prevalence of chronic pain in dementia is
between 30% and 80%.43 However, patients with AD do not
report pain as often and are prescribed analgesics less frequently,
compared with healthy age-matched individuals.34,129 Pain is a
key trigger for behavioural and psychological symptoms of
dementia such as agitation and mood disorders, which are a
major treatment challenge and can result in overprescribing of
harmful antipsychotic medications.10,52,123 Pathologically, the
basal forebrain and medial temporal lobe are amongst the first
regions affected before progression to neocortical regions.18,108
Notably, the sensory cortices remain relatively unaffected until
terminal stages. The significance of this is multifaceted: (1) the
regions affected partially overlap with regions implicated in the
processing of pain, (2) the regions affected are believed to be
involved more in emotional-affective rather than sensory-
discriminative dimensions, and (3) the cognitive deficits within
memory, attention, and communication render self-report of pain
increasingly unreliable with disease severity. Specifically, a
reduced capacity to comprehend and complete standardised
pain assessments as well as an overall reduction in reporting of
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pain.2,78,84,113 Therefore, altered pain processing (1 and 2) is
challenging to disentangle from a diminished capacity to
accurately provide self-report (3), highlighting the need for
investigation at a mechanistic level.
2.1. Pain processing is altered in Alzheimer disease
Many psychophysical studies investigating noxious stimuli have
demonstrated altered pain processing in AD compared with
healthy controls. However, the directionality of these changes
remain equivocal. Thresholds have been reported to be in-
creased15,35,66,106 or similar to cognitively intact con-
trols.15,81,79,82,93 Similarly, pain tolerance has been reported to
be reduced,11,35,79,82 equal,35,66,81,89,88 and increased.122 In
addition, behavioural responses to pain have been shown to be
augmented in AD,72,89,88 with enhanced facial responses
throughout the spectrum of disease severity.12 Patients with AD
have also shown a reduced threshold in the nociceptive flexion
reflex (NFR), possibly indicating differences in pain processing
further down the neuroaxis.89 Overall, disparities are likely due to
differences in pathophysiological mechanisms, disease pro-
gression, modalities of evoked pain used, and, crucially, outcome
measures used. Collectively, these findings allude to patients with
AD potentially suffering more despite reporting pain less.
Neuroimaging studies have suggested that neural activity in
patients with AD may be augmented in response to noxious
stimulation, despite relative preservation of sensory-
discriminative facets of pain. Patients show greater amplitude
and duration of blood oxygenation level dependent (BOLD)
signals (an indirect index of brain activity relating to neurovascular
coupling) during noxious pressure stimulation within sensory,
affective, and cognitive regions, including the dorsolateral
prefrontal cortex (dlPFC).35 Consistent with altered cognition
being functionally related to pain processing, patients also show
enhanced functional connectivity between the dlPFC and anterior
midcingulate, periaqueductal grey (PAG), thalamus, and hypo-
thalamus.36 Indeed, the dlPFC plays a central role in both general
cognitive function70 as well as pain modulation.95,130,149 Further-
more, diffusion tensor imaging has evidenced anatomical
connectivity between the right dlPFC, hypothalamus, and
PAG,71 in which activity has been associated with pain-related
escape responses in rodents.86,98 This may reflect a failure to
adequately contextualise and appraise painful experiences
resulting in uncertainty and a higher threat value ascribed to
noxious stimulation. Furthermore, a lack of contextualising
features within scanning environments may compound this.36
Delineation of the impact of context and setting warrants further
investigation. Collectively, neuroimaging studies indicate greater
emotional reactivity and pain processing, despite equal or mildly
diminished thresholds.
The implication of regions including the dlPFC, PAG, and
hypothalamus overlaps with the neural substrates of placebo
analgesia through which context and expectation can profoundly
alter treatment responses.36,118,150 Patients with AD with re-
duced frontal lobe function exhibited diminished placebo
responses in an open-hidden paradigm, requiring escalation of
analgesic dose.16 Furthermore, executive function is the domain
of cognition that best predicts variance in facial responsiveness to
noxious electrical stimulation and the NFR.90 Thus, patients with
milder disease severity may benefit more from analgesics
because of relative preservation of placebo mechanisms. The
placebo response is engaged in the administration of all
pharmacotherapy to some extent and accounts for a large
portion of the reduction in pain produced, over and above
Figure 1. Conceptual framework relating the respective neurodegenerative pathophysiology within AD and PD to pain processing and treatment. AD, Alzheimer
disease; PD, Parkinson disease.
Box 1. Definitions
Neurodegenerative disease: a heterogeneous group of disorders that are characterized by the progressive degeneration of the structure and function of the central nervous system
or peripheral nervous system.
Dementia: a syndrome that involves severe loss of cognitive abilities as a result of disease or injury. Dementia caused by traumatic brain injury is often static, whereas dementia
caused by neurodegenerative disorders, such as AD, is usually progressive and can eventually be fatal.
Alzheimer disease: a progressive neurodegenerative disease that impairs memory and cognitive judgment and is often accompanied by mood swings, disorientation, and
eventually delirium. The most common cause of dementia.
Parkinson disease: a progressive neurodegenerative disorder, characterized by motor symptoms, such as tremor, rigidity, slowness of movement, and problems with gait. Motor
symptoms are often accompanied with fatigue, depression, pain, and cognitive problems.
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pharmacological efficacy.14,17,37,148 Therefore, patients with
attenuated placebo responses should require larger doses to
produce the same level of analgesia as controls. Worryingly, as
AD and age progress, patients become increasingly frail, hence
dose escalation may be a major concern given that age is a
significant predictor of opioid-related harm.28,57,85 Placebo
analgesia and opioid analgesia partially share neuroanatomical
substrates; covariation has been observed between the activity in
the rostral anterior cingulate cortex (ACC) and the brainstem
during both placebo and opioid analgesia, but not during pain
alone.114,135 Postmortem AD brains also show reduced
m-/d-opioid receptor binding.104 Patients with AD may thus
present alterations in centrally mediated opioid analgesia. Further
application of open-hidden paradigms alongside pharmacoimag-
ing may offer insights into how the combined magnitude of
pharmacological and placebo analgesia can be maximised
clinically.
2.2. Pharmacotherapy of pain in Alzheimer disease
Overall, patients with AD seem to be prescribed fewer analgesics
than healthy individuals.10,73,128 Conversely, recent studies from
Scandinavia have reported an opposite trend.80,96,126
Paracetamol/acetaminophen remain the principal treatment for
mild-to-moderate pain in AD with additional use of nonsteroidal
anti-inflammatory drugs and opioids.3 However, studies pro-
viding mechanistic insight remain scarce.3,53 For example, of the
3 randomised control trials (RCTs) investigating opioids, 2 were
underpowered and in one investigating the buprenorphine
transdermal system, 23 of the 44 patients withdrew treatment
because of adverse events.52,97,101 No trials have investigated
antidepressants and antiepileptics.3,77 Further RCTs will be
necessary to not only produce evidence-based treatment
guidelines but also to provide insights into the putative
perturbation of neurotransmitter systems.
3. Parkinson disease
Pain is a prevalent nonmotor symptom in people with PD (PwP),
acknowledged by James Parkinson in 1817,112 affecting 68% to
85% of patients.13,23,103,116,127 Despite this, it remains under-
diagnosed and undertreated.6,31,41,58,83,156 Pain in PwP is
multifaceted and may result from comorbidities, be caused or
amplified by motor symptoms, and is subject to abnormal
nociceptive processing, as PD-specific neurodegeneration af-
fects peripheral, spinal, and cerebral pain pathways.42,125
Attempts have been made to synthesize a clear picture of
heterogeneous pain in PD (Table 1)6,58,151; however, to date, our
basic understanding of the relationship between PD pathophys-
iology and pain remains underdeveloped. Identifying well-defined
subtypes, and elucidating their concomitant underlying mecha-
nisms, should facilitate the development of personalised treat-
ment of pain in PwP.24,143
3.1. Pain processing is altered in Parkinson disease
Studies have largely reported reduced pain thresholds (greater
sensitivity to pain) and lower pain tolerance in PwP (for meta-
analysis, see Ref. 141). Interestingly, no relationship between
pain sensitivity and disease duration was reported across 26
studies.141 Moreover, significant heterogeneity is seen within and
across studies suggesting considerable interindividual differ-
ences with multiple contributory factors. Surveys have found
intensity and frequency of pain to be higher in patients with more
advanced PD; however, this likely reflects an increased incidence
of musculoskeletal pain.141 A study using quantitative sensory
testing failed to find a difference between drug-naive pain-free
patients and controls suggesting that abnormalities may arise
later in the disease duration, relate to dopaminergic therapy, or be
associated with the development of chronic pain.62 In the
absence of longitudinal investigation, the effects of disease
progression are impossible to delineate but the power advan-
tages of meta-analysis add credence to the possibility that
enhanced pain sensitivity is engaged at a certain point during
pathogenesis with a strong ceiling effect. Early pathophysiology
within the midbrain and brainstem regions may therefore be
important for elevated psychophysical pain sensitivity and
reduced pain thresholds. Conversely, conditioned pain modula-
tion paradigms, which assess the functionality of descending
modulatory mechanisms, have been found to be comparable in
controls and patients with PD in both ON and OFF states.68,69
However, trend significant differences were seen between PD
subtypes (akinetic rigid, tremor dominant, and mixed). Given the
low power of the study, this supports the heterogeneity of pain
processing in PwP and emphasises the need for large studies
that allow for adequately powered substratification.
Functional magnetic resonance imaging has revealed malad-
aptation of pain networks present even at early disease stages in
pain-free PwP compared with healthy controls. Increased pain-
related BOLD activation was observed in the somatosensory
cortex, cerebellum, and caudal pons.138 Furthermore, activity in
descending pain modulatory regions, such as the dlPFC, dorsal
ACC, and subgenual ACC, is lower in PwP than in healthy
individuals, and connectivity between dorsal ACC and dlPFC
during anticipation of pain is reduced.138 The bilateral activation
of the nucleus accumbens (NA) in PwP is also lower than that in
healthy controls, suggesting altered processing of cognitive and
evaluative facets of pain.120,140 A network-based analysis has
shown dysfunction in reward pathways in PwP suffering from
persistent pain, but not those without, with disconnection of the
Figure 2. Importance of mechanistic research for evidence-based pain medicine.
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right NA and left hippocampus.118 TheNAhas been implicated in the
transition from acute to chronic pain across a variety of human and
animal studies.8,29,51,56,155 Thedirection of causality remains unclear,
but dysfunction of reward andmodulatory networksmay predispose
PwP to develop chronic pain and offer therapeutic targets.
3.2. Pharmacotherapy of pain in Parkinson disease
Pain in PwP remains neglected and poorly understood, with only
aminority of patients receiving adequate treatment.13 People with
PD are more likely to be prescribed analgesics, such as opiates,
acetaminophen, antiepileptics, and antidepressants, as well as
receive chronic prescriptions, risking polypharmacy or burden-
some side effects.22 Dopaminergic replacement therapy might
lead to pain relief in some PwP.92,142 For example, a 2-fold
improvement in the King’s Parkinson Disease Pain Scale domain
“fluctuation-related pain” was observed with rotigotine vs
placebo.124 L-Dopa administration reversed the reduction of pain
threshold seen in PwP during the off-state64 and normalised
abnormally increased pain-related activation within sensory-
discriminative (insula) and cognitive-affective (prefrontal cortex
and ACC) regions in a positron emission tomography study.21
Interestingly, pain reduction from L-dopa administration or deep
brain stimulation [for review, see; Refs. 39,45,91] does not
correlate with motor improvement suggesting it may act directly
on pain circuitry.40,92,102,142 L-Dopa is not only converted
exclusively into dopamine but also into noradrenaline and may
act as a false neurotransmitter within serotonergic terminals.50 As
both monoamines play a role in descending pain modulation and
are affected by PD-specific neurodegenerative changes at
prodromal stages, the pain modifying effect of L-dopa may be
partially mediated through nondopaminergic systems.9,19,20,44,74
Accordingly, duloxetine led to some degree of pain relief in an
open-label study.49 Cannabis has shown an ability to markedly
reduce both sensory and affective facets of pain in PwP.132
Interestingly, an oxycodone RCT failed to reach significance for
the primary end point of reducing 24 hour pain scores.144 There
was a trend reduction in pain, and the dosage may have been
inadequate. However, opioidergic circuitry is known to be
perturbed by PD pathophysiology, and this may affect the
efficacy of opioid analgesia.54,115,136,140 Safinamide, with actions
on dopamine through monoamine oxidase-B inhibition as well as
modulating abnormal glutamate release, has also shown a
benefit in PwP.26,27,65 Rotigotine, a purely dopaminergic agonist,
produces limited benefit for overall pain in PwP suggesting that
safinamide may well impart a benefit through glutamatergic
actions and this warrants future investigation.124 However, there
remains a paucity of robust studies with the Movement Disorder
Society non-motor symptoms treatment recommendation iden-
tifying only 2 as sufficiently high quality to include.131 The
multiplicity of neurotransmitter systems through which these
drugs act eludes to the complexity of pain in PD. Future research
should use refined populations, or those large enough for
substratification, to further elucidate how these interventions
differentially interact with PD subtypes.
3.3. Utility of animal models
Animal models offer a unique opportunity to probe mechanisms
of pain and pharmacotherapy. This has been well reviewed for
PD,55,147 but remains understudied in AD. Mirroring clinical
populations most studies report altered pain thresholds com-
pared with controls.7,59,67,94,99,105,133,137 A chemically induced
model of osteoarthritis through an intra-articular injection of
monosodium iodoacetate within transgenic TASTPM AD mice
has provided insights into interactions between clinically relevant
pain, neurodegenerative pathophysiology, and opioid analge-
sia.4,5 TASTPM mice demonstrate an age-dependent reduction
in thermal nociception that coincides with amyloid pathology in
pain-related brain regions.4 Naloxone, an opioid antagonist,
Table 1
Overview of the classification systems to date for pain in
people with Parkinson disease.
Quinn et al.121 A) Pain preceding diagnosis of Parkinson disease
B) Off-period pain (without dystonia) in patients with





C) Painful dystonic spasms





Ford61 1. Musculoskeletal (aching, cramping, arthralgic,
and myalgic sensations in joints and muscles)
2. Radicular/neuropathic (pain in a root or nerve
territory)
3. Dystonia (associated with sustained twisting
movements and postures)
4. Central or primary pain (burning, tingling,
formication, and “neuropathic” sensations, often
relentless and bizarre in quality)
5. Akathisia (subjective sense of restlessness, often
accompanied by an urge to move)
Wasner and deuschl151 A) Pain related to Parkinson disease:
1. Nociceptive: Musculoskeletal (joint pain,
pain linked to motor fluctuations—dystonic or
nondystonic, back pain, and pain linked to
autonomic failure), visceral (abdominal pain,
gastrointestinal discomfort, constipation, and
involuntary dystonic contraction of anal sphincter),
and cutaneous (pressure sores)
2. Neuropathic: Peripheral (radicular) or
central Parkinson pain
3. Miscellaneous: pain preceding Parkinson
disease, pain linked to restless leg syndrome and
akathisia, and pain linked to depression.
B) Pain unrelated to Parkinson disease —different
pain syndromes.
Chaudhuri et al.32 1. Musculoskeletal pain (pain around joints)
2. Chronic pain (a generalised constant, dull, aching
pain or pain related to an internal organ)
3. Fluctuation-related pain (dyskinetic pain, “off”-
period dystonia, and generalised “off”-period pain)
4. Nocturnal pain (pain related to periodic limb
movement and restless leg syndrome or pain
related to difficulties turning around in bed)
5. Oro-facial pain (pain when chewing, pain due to
grinding the teeth, and burning mouth syndrome)
6. Discolouration/oedema and swelling (burning
pain in limbs and generalised lower abdominal pain)
7. Radicular pain (a shooting pain/pins and needles
down the limbs)
Mylius et al.107 A) Non–Parkinson disease-related pain
B) Parkinson disease-related pain:
1. Musculoskeletal pain
2. Psychomotor restlessness pain
3. Neuropathic pain
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restored thermal nociceptive thresholds to that of wild-type
controls. Mice modelling with combined AD and osteoarthritis
exhibited impaired mechanical hypersensitivity and a lack of
weight asymmetry. Subsequent administration of morphine not
only produced an antinociceptive effect but also increased the
noxious threshold significantly greater than that seen in wild-type
animals.5 Conversely, gabapentin showed no efficacy. Thus,
altered processing within opioidergic circuitry may partially
mediate altered pain processing as well as influence both efficacy
and centrally mediated side effects of opioidergic pharmacother-
apy. Additional preclinical investigation may yield similar avenues
for translational investigation.
4. Conclusion
Pain processing is altered in both AD and PD, but research to date
has been focussed on evoked pain. During chronic pain, structural
and functional reorganisation that takes place can be conceptual-
ised as normal pain processing by the nervous system interacting
with a given aetiology to produce a novel chronic pain brain
state.146 These perturbed states further interact with neurodegen-
erative pathophysiology in amanner yet to be investigated;whether
this produces differential responses to analgesic pharmacotherapy
to those seen in the general population remains unclear. However,
the theoretical basis outlined here is compelling and mechanistic-
level investigation will be crucial to translate our emerging
understanding of dysfunctional pain processing to inform safe
and effective clinical management. Although our focus here has
been on AD and PD, these constructs likely extend to other
neurodegenerative diseases that require similarmechanism-based
investigation to facilitate therapeutic development.
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